Literature DB >> 26207228

Roscovitine in cancer and other diseases.

Jonas Cicenas1, Karthik Kalyan1, Aleksandras Sorokinas1, Edvinas Stankunas1, Josh Levy1, Ingrida Meskinyte1, Vaidotas Stankevicius1, Algirdas Kaupinis1, Mindaugas Valius1.   

Abstract

Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small molecule that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a broad-range purine inhibitor, which inhibits CDK1, CDK2, CDK5 and CDK7, but is a poor inhibitor for CDK4 and CDK6. Roscovitine is widely used as a biological tool in cell cycle, cancer, apoptosis and neurobiology studies. Moreover, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, inflammation, viral infections, polycystic kidney disease and glomerulonephritis. This review focuses on the use of roscovitine in the disease model as well as clinical model research.

Entities:  

Keywords:  Cyclin-dependent kinases (CDK); cancer; kidney diseases; neurodegeneration; roscovitine; small molecule inhibitor

Year:  2015        PMID： 26207228      PMCID： PMC4486920          DOI： 10.3978/j.issn.2305-5839.2015.03.61

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  79 in total

1.  Protective effect of roscovitine on renal ischemia-reperfusion injury.

Authors:  A Aydemir; O Abbasoglu; S Topaloglu; D Ertoy; A Ayhan; K Kilinç; E Karabulut; I Sayek
Journal:  Transplant Proc       Date:  2002-09       Impact factor: 1.066

Review 2.  Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.

Authors:  Peter M Fischer; Athos Gianella-Borradori
Journal:  Expert Opin Investig Drugs       Date:  2005-04       Impact factor: 6.206

3.  Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.

Authors:  Shannon L Maude; Greg H Enders
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

4.  Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine.

Authors:  Christina Patrick; Leslie Crews; Paula Desplats; Wilmar Dumaop; Edward Rockenstein; Cristian L Achim; Ian P Everall; Eliezer Masliah
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

5.  Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

Authors:  Nikolay O Bukanov; Laurie A Smith; Katherine W Klinger; Steven R Ledbetter; Oxana Ibraghimov-Beskrovnaya
Journal:  Nature       Date:  2006-11-22       Impact factor: 49.962

6.  Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.

Authors:  Miguel Abal; Rui Bras-Goncalves; Jean-Gabriel Judde; Hafida Fsihi; Patricia De Cremoux; Daniel Louvard; Henri Magdelenat; Sylvie Robine; Marie-France Poupon
Journal:  Oncogene       Date:  2004-03-04       Impact factor: 9.867

7.  Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2.

Authors:  Subhra Mohapatra; Baoky Chu; Sheng Wei; Julie Djeu; P K Epling-Burnette; Thomas Loughran; Richard Jove; W Jackson Pledger
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

8.  Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine.

Authors:  Juan Sebastian Yakisich; Marina Fernanda Vita; Ake Siden; Deborah Ruth Tasat; Mabel Cruz
Journal:  Invest New Drugs       Date:  2009-04-24       Impact factor: 3.850

9.  Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.

Authors:  Laurence Maggiorella; Eric Deutsch; Valérie Frascogna; Nicole Chavaudra; Laurence Jeanson; Fabien Milliat; François Eschwege; Jean Bourhis
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

10.  Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model.

Authors:  Katie L Martin; Grace A Hill; Rob R Klein; Deborah G Arnett; Randy Burd; Kirsten H Limesand
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240
View more
  68 in total

1.  Cell Cycle-dependent Changes in Localization and Phosphorylation of the Plasma Membrane Kv2.1 K+ Channel Impact Endoplasmic Reticulum Membrane Contact Sites in COS-1 Cells.

Authors:  Melanie M Cobb; Daniel C Austin; Jon T Sack; James S Trimmer
Journal:  J Biol Chem       Date:  2015-10-06       Impact factor: 5.157

2.  NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2.

Authors:  Donglin Ding; Huixing Huang; Quanfu Li; Wenbo Yu; Chenji Wang; Haijie Ma; Jiaxue Wu; Yongjun Dang; Long Yu; Wei Jiang
Journal:  Cell Death Discov       Date:  2020-01-22

3.  The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.

Authors:  Leslie A Parsels; Joshua D Parsels; Daria M Tanska; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

4.  Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.

Authors:  Tamara B Garcia; Susan P Fosmire; Christopher C Porter
Journal:  Leuk Res       Date:  2017-11-11       Impact factor: 3.156

5.  Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.

Authors:  David Askew; Tej K Pareek; Saada Eid; Sudipto Ganguly; Megan Tyler; Alex Y Huang; John J Letterio; Kenneth R Cooke
Journal:  Blood       Date:  2016-11-14       Impact factor: 22.113

6.  Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.

Authors:  Olivia Morris-Hanon; Mariela Claudia Marazita; Leonardo Romorini; Luciana Isaja; Damián Darío Fernandez-Espinosa; Gustavo Emilio Sevlever; María Elida Scassa; Guillermo Agustín Videla-Richardson
Journal:  Mol Neurobiol       Date:  2019-05-23       Impact factor: 5.590

Review 7.  Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Authors:  Stephen D Meriney; Tyler B Tarr; Kristine S Ojala; Man Wu; Yizhi Li; David Lacomis; Adolfo Garcia-Ocaña; Mary Liang; Guillermo Valdomir; Peter Wipf
Journal:  Ann N Y Acad Sci       Date:  2017-11-10       Impact factor: 5.691

8.  YY1 regulated transcription-based stratification of gastric tumors and identification of potential therapeutic candidates.

Authors:  Divya Bhaskar Rao; Ponmathi Panneerpandian; Karthik Balakrishnan; Kumaresan Ganesan
Journal:  J Cell Commun Signal       Date:  2021-02-23       Impact factor: 5.782

Review 9.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

10.  Rapid, quantitative therapeutic screening for Alzheimer's enzymes enabled by optimal signal transduction with transistors.

Authors:  Son T Le; Michelle A Morris; Antonio Cardone; Nicholas B Guros; Jeffery B Klauda; Brent A Sperling; Curt A Richter; Harish C Pant; Arvind Balijepalli
Journal:  Analyst       Date:  2020-03-11       Impact factor: 4.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.